Asian Patient Access Program (APAP)
Simplifying Access to Innovative Medicines
for Asia’s Self-Paying Patients
APAP is a groundbreaking initiative designed to bridge the gap in medical access for patients across Asia.
- Provides immediate access to advanced medications tailored for self-paying patients in Asia.
- Eliminates the need for local registration processes, simplifying approvals.
- Addresses the critical medical needs of 173 million rare disease patients across 48 Asian countries.
- Delivers a seamless and efficient process with measurable outcomes.
The program offers three tailored solutions to meet the diverse needs of Asian patients and originators:
APAP offers a flexible gateway to Asian markets, delivering immediate results while complementing Macau’s registration pathway to maximize opportunities and ensure sustainable growth.
New York-Based Asian Patient Access Program
Asian Local Patient Access Program (Macau & Singapore)
Macau Fast-Track Registration Program
New York-Based Asian Patient Access Program
Objective:
- Leverage ACA Pharma’s U.S. wholesale accounts to deliver treatments directly to self-paying patients in Asia, bypassing local registration processes.
Key Features:
- Originators authorize new drugs to be added to ACA Pharma’s U.S. wholesale accounts (e.g., ICS, ASD Healthcare, AmerisourceBergen), ensuring smooth and efficient access.
- Medications are delivered through temporary import permits issued by local governments for hospitals or individual patients, addressing urgent patient needs.
- Backed by ACA Pharma’s 30+ years of experience and an extensive network of specialty healthcare providers across Asia.
- Eliminates the need for local registrations, reducing regulatory barriers and mitigating geopolitical risks.
- Ensures rapid market entry, providing patients timely access to advanced and life-saving treatments.
Asian Local Patient Access Program (Macau & Singapore)
Objective:
- Establish local patient access programs after fast-track registration in Macau and Singapore.
Key Features:
- Expedited registration processes are exempt from clinical trials.
- Programs designed for self-paying patients across Asia, using U.S. retail or European market pricing.
- Provides open channels for timely treatment while addressing regional policy sensitivities.
Macau Fast-Track Registration Program
Objective:
- Rapidly access major markets like the Guangdong Greater Bay Area, Beijing, and Shanghai with a streamlined 30-90 day registration process.
Key Features:
- Facilitates real-world data collection to support national approvals.
- Provides a foundation for broader access through the Asian Patient Access Program.
Why Choose ACA Pharma?
- 30+ Years of Expertise: Extensive experience in Asia’s pharmaceutical industry.
- Established Network: Collaborations with leading doctors, hospitals, and distributors.
- Proven Success: 54 drugs registered, 7 more in progress, benefiting millions of patients.
- Flexible Solutions: Tailored programs that adapt to Originators’ needs.
Dual-Path Strategy: Immediate Results and Long-Term Growth
Drawing on ACA Pharma’s deep understanding of the growing demand for innovative therapies post-launch, our Strategic Dual-Path Approach provides originators with tailored options to meet their strategic goals:
- Immediate and Low-Risk Entry: Fast, efficient, and hassle-free
APAP enables originators to enter Asian markets rapidly, bypassing local registration and reducing complexity for immediate impact. - Long-Term Market Expansion: Building sustainable growth with strategic foresight
Macau’s registration pathway supports broader access, including hospitals, pharmacies, and national insurance systems, paving the way for lasting success. - Flexible and Adaptable Strategy: Customized solutions for dynamic market needs
Dual pathways provide originators with flexibility to address diverse market challenges and maximize opportunities.
Your local partner on the ground
Let us help you expedite your registration in Macau for China access today!
